FDA cancels Cymbalta meeting

FDA cancelled the Jan. 28 meeting of its Anesthetic and Life Support Drugs Advisory Committee to discuss an sNDA for Cymbalta duloxetine from Eli Lilly and Co. (NYSE:LLY) to treat chronic pain. FDA said the meeting was cancelled to allow time to review new information that relates to the benefit-risk balance for the proposed new indication. Lilly said it had submitted one new efficacy/safety study. ...